Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Science 37 enrolls 65 patients per month for its sponsor's Phase 3 infectious disease clinical trial.
-
Nearly 20 studies have successfully leveraged Science 37's medical and operational expertise to boost patient recruitment and enrollment activities.
-
Science 37, a leader in enhancing patient access to clinical trials, surpasses enrollment targets and helps accelerate Phase 2 rare disease study.
-
Science 37, a leader in enhancing patient access to clinical trials, surpasses enrollment targets and helps accelerate Phase 2 rare disease study.
-
Science 37 Holdings, Inc. today announced the preliminary outcome of its recent FDA Inspection focusing on critical areas and documentation.
-
Science 37 announces its selection as the winner of the “Clinical Efficiency Innovation Award” in the 8th annual MedTech Breakthrough Awards program.
-
Science 37's Metasite™ and Patient Recruitment Solutions together dramatically boost patient enrollment in a Phase 3 asthma clinical trial.
-
Science 37's Patient Recruitment Solution provides fully-consented patients to clinical trial sites to supplement enrollment.
-
RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (the “Company” or “Science 37”), the clinical research industry’s leading MetasiteTM, today...
-
RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™ today announced that it has been named a...